Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease

Hidekazu Tomimoto, Ichiro Akiguchi, Ryo Ohtani, Hideo Yagi, Satoshi Ogura, Hideaki Wakita

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The blood coagulation system has been shown to be activated in subacute exacerbations of Binswanger disease (BD). In our previous study, the antithrombin drug argatroban ameliorated the neurological exacerbations in a BD patient with antiphospholipid antibody syndrome. We have further examined the therapeutic efficacy of argatroban in 3 BD patients with subacute exacerbations, but without any immune-mediated prothrombotic complications. In 1 out of these 4 patients, treatment with sodium ozagrel, an antiplatelet drug was applied, but was ineffective. In all patients, argatroban treatment reduced the levels of the hemostatic markers, with a corresponding improvement in cognitive dysfunction and gait disorders. These results suggest that the antithrombin effect is true also for BD patients not compromised by the immune-mediated prothrombotic condition.

Original languageEnglish
Pages (from-to)966-969
Number of pages4
JournalInternal Medicine
Volume39
Issue number11
DOIs
Publication statusPublished - 01-01-2000

Fingerprint

Vascular Dementia
Antithrombins
Pharmaceutical Preparations
Antiphospholipid Syndrome
Platelet Aggregation Inhibitors
Blood Coagulation
Hemostatics
Gait
Therapeutics
argatroban

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Tomimoto, Hidekazu ; Akiguchi, Ichiro ; Ohtani, Ryo ; Yagi, Hideo ; Ogura, Satoshi ; Wakita, Hideaki. / Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease. In: Internal Medicine. 2000 ; Vol. 39, No. 11. pp. 966-969.
@article{a2cde5b78e684a35abab59405a239bcd,
title = "Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease",
abstract = "The blood coagulation system has been shown to be activated in subacute exacerbations of Binswanger disease (BD). In our previous study, the antithrombin drug argatroban ameliorated the neurological exacerbations in a BD patient with antiphospholipid antibody syndrome. We have further examined the therapeutic efficacy of argatroban in 3 BD patients with subacute exacerbations, but without any immune-mediated prothrombotic complications. In 1 out of these 4 patients, treatment with sodium ozagrel, an antiplatelet drug was applied, but was ineffective. In all patients, argatroban treatment reduced the levels of the hemostatic markers, with a corresponding improvement in cognitive dysfunction and gait disorders. These results suggest that the antithrombin effect is true also for BD patients not compromised by the immune-mediated prothrombotic condition.",
author = "Hidekazu Tomimoto and Ichiro Akiguchi and Ryo Ohtani and Hideo Yagi and Satoshi Ogura and Hideaki Wakita",
year = "2000",
month = "1",
day = "1",
doi = "10.2169/internalmedicine.39.966",
language = "English",
volume = "39",
pages = "966--969",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "11",

}

Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease. / Tomimoto, Hidekazu; Akiguchi, Ichiro; Ohtani, Ryo; Yagi, Hideo; Ogura, Satoshi; Wakita, Hideaki.

In: Internal Medicine, Vol. 39, No. 11, 01.01.2000, p. 966-969.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease

AU - Tomimoto, Hidekazu

AU - Akiguchi, Ichiro

AU - Ohtani, Ryo

AU - Yagi, Hideo

AU - Ogura, Satoshi

AU - Wakita, Hideaki

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The blood coagulation system has been shown to be activated in subacute exacerbations of Binswanger disease (BD). In our previous study, the antithrombin drug argatroban ameliorated the neurological exacerbations in a BD patient with antiphospholipid antibody syndrome. We have further examined the therapeutic efficacy of argatroban in 3 BD patients with subacute exacerbations, but without any immune-mediated prothrombotic complications. In 1 out of these 4 patients, treatment with sodium ozagrel, an antiplatelet drug was applied, but was ineffective. In all patients, argatroban treatment reduced the levels of the hemostatic markers, with a corresponding improvement in cognitive dysfunction and gait disorders. These results suggest that the antithrombin effect is true also for BD patients not compromised by the immune-mediated prothrombotic condition.

AB - The blood coagulation system has been shown to be activated in subacute exacerbations of Binswanger disease (BD). In our previous study, the antithrombin drug argatroban ameliorated the neurological exacerbations in a BD patient with antiphospholipid antibody syndrome. We have further examined the therapeutic efficacy of argatroban in 3 BD patients with subacute exacerbations, but without any immune-mediated prothrombotic complications. In 1 out of these 4 patients, treatment with sodium ozagrel, an antiplatelet drug was applied, but was ineffective. In all patients, argatroban treatment reduced the levels of the hemostatic markers, with a corresponding improvement in cognitive dysfunction and gait disorders. These results suggest that the antithrombin effect is true also for BD patients not compromised by the immune-mediated prothrombotic condition.

UR - http://www.scopus.com/inward/record.url?scp=0034327968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034327968&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.39.966

DO - 10.2169/internalmedicine.39.966

M3 - Article

VL - 39

SP - 966

EP - 969

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 11

ER -